NeoGenomics (NEO) Investor Presentation - Slideshow

Company Overview - NeoGenomics is a leading oncology testing company, serving over 2,600 hospitals and cancer centers[8] - The company performs approximately 1,000,000 tests per year, serving around 500,000 patients annually[8] - Pharma Services backlog is approximately $173 million[9] Market and Growth - The oncology test market is estimated to grow at a rate of 6% to 8%[10] - The number of U S cancer survivors is projected to reach 26 1 million by 2040[13] - The company looks to grow twice the market rate, driven by company-specific growth drivers[21, 22] Financial Performance (Q2 2020) - Pharma Services new business reached $40 million[35] - Pharma Services backlog increased by 63% year-over-year[35] - Clinical Services revenue for Q2 2020 was $73 884 million, a decrease of 17 0% compared to Q2 2019 ($88 982 million)[66] - Pharma Services revenue for Q2 2020 was $13 093 million, an increase of 2 8% compared to Q2 2019 ($12 731 million)[66]